Kantarjian et al53 assessed the efficacy and protection of dasatinib, as compared with imatinib, for the very first-line cure of CML-CP. Five hundred and nineteen individuals with newly diagnosed CML-CP had been randomly assigned to obtain dasatinib at a dose of 100 mg as soon as day-to-day (259 individuals) or https://joschkal419chl2.losblogos.com/profile